|
answer text |
<p>NHS England and NHS Improvement and the National Institute for Health and Care
Excellence (NICE) have agreed principles to allow potential interim access to medicines
licensed through Project Orbis, where there is a gap between licensing and publication
of NICE’s guidance. NHS England and NHS Improvement are continuing discussions with
Gilead, to urge the company to support interim access arrangements in line with the
agreed principles. NICE expects to issue draft guidance on Trodelvy in spring 2022
with final guidance in June 2022.</p>
|
|